MAPK7 and prostate carcinoma: A decrease in overall and disease-free survival for patients with elevated ERK5 levels has been seen in prostate cancer (Mehta et al., 2003), breast cancer (Ortiz-Ruiz et al., 2014; Miranda et al., 2015; Xu et al., 2021), lung cancer (Jiang et al., 2020; Sánchez-Fdez et al., 2021), colorectal cancer (Simões et al., 2015; Pereira et al., 2016), glioma (Carmell et al., 2021), osteosarcoma (Tesser-Gamba et al., 2012) and melanoma (Tusa et al., 2018).